Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Amortization of Deferred Charges (2025)

NewAmsterdam Pharma's Amortization of Deferred Charges history spans 1 years, with the latest figure at -$24000.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to -$24000.0; the TTM value through Dec 2025 reached -$1.4 million, changed N/A, while the annual FY2025 figure was -$1.4 million, 518.94% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was -$24000.0 at NewAmsterdam Pharma, up from -$396000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at -$24000.0 in Q4 2025 and bottomed at -$513000.0 in Q1 2025.